Simon Call

Muenster, NW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Chimeric antigen receptor T-cell therapy is equally effective and safe in older (≥70) and younger patients with multiple myeloma: a multicenter retrospective analysis.

Chimeric antigen receptor T-cell therapy is equally effective and safe in older (≥70) and younger patients with multiple myeloma: a multicenter retrospective analysis.

Journal: Blood cancer journal

Published: November 08, 2025

Relapse after allogeneic hematopoietic stem cell transplantation in patients with active acute myeloid leukemia.

Relapse after allogeneic hematopoietic stem cell transplantation in patients with active acute myeloid leukemia.

Journal: Leukemia research

Published: October 06, 2025

Immune reconstitution in AML and MDS patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) with treosulfan- or TBI-based conditioning.

Immune reconstitution in AML and MDS patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) with treosulfan- or TBI-based conditioning.

Journal: Bone marrow transplantation

Published: May 02, 2025

High-Dose Melphalan Followed by Busulfan and Fludarabine Conditioning Prior to Allogeneic Stem Cell Transplantation in Elderly Patients with Active Acute Myeloid Leukemia-A Retrospective Single-Center Study.

High-Dose Melphalan Followed by Busulfan and Fludarabine Conditioning Prior to Allogeneic Stem Cell Transplantation in Elderly Patients with Active Acute Myeloid Leukemia-A Retrospective Single-Center Study.

Journal: Transplantation and cellular therapy

Published: March 19, 2025

Efficacy of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma and prior central nervous system manifestation: A multicenter real-world analysis.

Efficacy of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma and prior central nervous system manifestation: A multicenter real-world analysis.

Journal: HemaSphere

Published: January 30, 2025

Remission conversion drives outcomes after CAR T-cell therapy for multiple myeloma: a registry analysis from the DRST.

Remission conversion drives outcomes after CAR T-cell therapy for multiple myeloma: a registry analysis from the DRST.

Journal: Blood

Published: January 03, 2025

The CXCL16/CXCR6 axis is linked to immune effector cell-associated neurotoxicity in chimeric antigen receptor (CAR) T cell therapy.

The CXCL16/CXCR6 axis is linked to immune effector cell-associated neurotoxicity in chimeric antigen receptor (CAR) T cell therapy.

Journal: Genome medicine

Published: October 31, 2024

Common hereditary variants of the APOE gene and posttransplant outcome in acute myeloid leukemia.

Common hereditary variants of the APOE gene and posttransplant outcome in acute myeloid leukemia.

Journal: Blood

Published: September 10, 2024

Early blast clearance during sequential conditioning prior to allogeneic stem cell transplantation in patients with acute myeloid leukaemia.

Early blast clearance during sequential conditioning prior to allogeneic stem cell transplantation in patients with acute myeloid leukaemia.

Journal: British journal of haematology

Published: February 15, 2024

Comparable outcomes for TBI-based versus treosulfan based conditioning prior to allogeneic hematopoietic stem cell transplantation in AML and MDS patients.

Comparable outcomes for TBI-based versus treosulfan based conditioning prior to allogeneic hematopoietic stem cell transplantation in AML and MDS patients.

Journal: Bone marrow transplantation

Published: February 04, 2024

Chimeric antigen receptor-T cell therapy shows similar efficacy and toxicity in patients with diffuse large B-cell lymphoma aged 70 and older compared to younger patients: A multicenter cohort study.

Chimeric antigen receptor-T cell therapy shows similar efficacy and toxicity in patients with diffuse large B-cell lymphoma aged 70 and older compared to younger patients: A multicenter cohort study.

Journal: HemaSphere

Published: December 07, 2023

Prevalence and clinical impact of CD56 and T-cell marker expression in acute myeloid leukaemia: A single-centre retrospective analysis.

Prevalence and clinical impact of CD56 and T-cell marker expression in acute myeloid leukaemia: A single-centre retrospective analysis.

Journal: EJHaem

Published: August 07, 2023

Showing 1-12 of 15

Last Updated: 09/26/2026